10-Hydroxy-2-decenoic acid (10-HDA), a bioactive component of royal jelly, exhibits significant pharmacological value in various applications. To date, its biosynthesis has been reported exclusively in endotoxin-prone Escherichia coli, which limits its biomedical utility. In this study, we successfully engineered the Generally Recognized As Safe (GRAS) yeast Saccharomyces cerevisiae as a biosynthetic platform for producing 10-HDA, thereby addressing the limitations associated with E. coli systems. By rewiring the β-oxidation pathway, combining compartmentalization with chaperone-assisted P450 folding in mitochondria, and enhancing NADPH supply, a yield of 40.50 mg/L of 10-HDA was achieved using 100 mg/L decanoic acid as the substrate. Finally, to mitigate substrate toxicity, fed-batch fermentation using ethyl decanoate increased production 7.5-fold, reaching 298.6 mg/L, which is the highest titer reported in yeast to date. This GRAS-compliant platform not only facilitates the safe and efficient production of 10-HDA but also establishes a novel paradigm for the functional expression of prokaryotic P450 enzymes in yeast.

• PMID: 40354551
• DOI full text
• PubMed
• PubTator

Reference Type

Journal Article

Authors

Su C, Wang Z, Zhang G, Wang T, Su Y, Liu Y, Wang R, Li P, Wang J, Wang T, ... Show all

Primary Lit For

Additional Lit For

Review For